Docetaxel and gemcitabine: a nonplatinum combination for non small-cell lung cancer

A. J. Olszanski; J. R. Rigas

doi:10.3816/clc.2000.s.003

Docetaxel and gemcitabine: a nonplatinum combination for non small-cell lung cancer

Research output: Contribution to journal › Article › peer-review

Abstract

The 1990s have introduced a number of novel chemotherapeutic agents with activity in non small-cell lung carcinoma. Docetaxel and gemcitabine appear to be two of the most active new agents. Their use in non small- cell lung carcinoma has been associated with improvements in survival, palliation of symptoms, and maintenance of quality of life when compared to best supportive care. Options for treatment of non small-cell lung carcinoma after platinum have been limited. These newer agents have substantial activity in this subset of patients. This review focuses on the current data using the combination of docetaxel and gemcitabine in the fight against non small-cell lung carcinoma.

Original language	English
Pages (from-to)	S15-9
Journal	Clinical Lung Cancer
Volume	1 Suppl 1
DOIs	https://doi.org/10.3816/clc.2000.s.003
State	Published - 2000

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.3816/clc.2000.s.003

Cite this

@article{a65c4f5cf89b4a679093fa409ffc2bc0,

title = "Docetaxel and gemcitabine: a nonplatinum combination for non small-cell lung cancer",

abstract = "The 1990s have introduced a number of novel chemotherapeutic agents with activity in non small-cell lung carcinoma. Docetaxel and gemcitabine appear to be two of the most active new agents. Their use in non small- cell lung carcinoma has been associated with improvements in survival, palliation of symptoms, and maintenance of quality of life when compared to best supportive care. Options for treatment of non small-cell lung carcinoma after platinum have been limited. These newer agents have substantial activity in this subset of patients. This review focuses on the current data using the combination of docetaxel and gemcitabine in the fight against non small-cell lung carcinoma.",

author = "Olszanski, {A. J.} and Rigas, {J. R.}",

note = "Olszanski, A J Rigas, J R Journal Article United States 2004/01/17 Clin Lung Cancer. 2000 Apr;1 Suppl 1:S15-9. doi: 10.3816/clc.2000.s.003.",

year = "2000",

doi = "10.3816/clc.2000.s.003",

language = "English",

volume = "1 Suppl 1",

pages = "S15--9",

journal = "Clinical Lung Cancer",

issn = "1525-7304",

publisher = "Elsevier Inc.",

}

TY - JOUR

T1 - Docetaxel and gemcitabine: a nonplatinum combination for non small-cell lung cancer

AU - Olszanski, A. J.

AU - Rigas, J. R.

N1 - Olszanski, A J Rigas, J R Journal Article United States 2004/01/17 Clin Lung Cancer. 2000 Apr;1 Suppl 1:S15-9. doi: 10.3816/clc.2000.s.003.

PY - 2000

Y1 - 2000

N2 - The 1990s have introduced a number of novel chemotherapeutic agents with activity in non small-cell lung carcinoma. Docetaxel and gemcitabine appear to be two of the most active new agents. Their use in non small- cell lung carcinoma has been associated with improvements in survival, palliation of symptoms, and maintenance of quality of life when compared to best supportive care. Options for treatment of non small-cell lung carcinoma after platinum have been limited. These newer agents have substantial activity in this subset of patients. This review focuses on the current data using the combination of docetaxel and gemcitabine in the fight against non small-cell lung carcinoma.

AB - The 1990s have introduced a number of novel chemotherapeutic agents with activity in non small-cell lung carcinoma. Docetaxel and gemcitabine appear to be two of the most active new agents. Their use in non small- cell lung carcinoma has been associated with improvements in survival, palliation of symptoms, and maintenance of quality of life when compared to best supportive care. Options for treatment of non small-cell lung carcinoma after platinum have been limited. These newer agents have substantial activity in this subset of patients. This review focuses on the current data using the combination of docetaxel and gemcitabine in the fight against non small-cell lung carcinoma.

U2 - 10.3816/clc.2000.s.003

DO - 10.3816/clc.2000.s.003

M3 - Article

SN - 1525-7304

VL - 1 Suppl 1

SP - S15-9

JO - Clinical Lung Cancer

JF - Clinical Lung Cancer

ER -